Puma Biotechnology | PBYI - Acreedores Comerciales

Precio De Mercado
7.78
Cambio Diario
-0.02 -0.26%
Mensual
29.67%
Anual
175.89%
Q2 Expectativa
7.57




Acreedores Comerciales Cambio Fecha
Agios Pharmaceuticals USD 18.36M 1.2M 2025-12
Alnylam Pharmaceuticals USD 115.72M 1.87M 2025-12
Amgen USD 20.89B 1.25B 2025-12
Biogen USD 432M 18.9M 2025-12
BioMarin Pharmaceutical USD 759.03M 39.41M 2025-12
Daiichi Sankyo JPY 568.5B 16.84B 2025-12
Esperion Therapeutics USD 65.07M 12.44M 2025-12
Exelixis USD 29.62M 4.27M 2025-12
Gilead Sciences USD 808M 226M 2025-09
Glaxosmithkline GBP 20.72B 346.14M 2025-12
Incyte USD 1.63B 1.46B 2025-12
MacroGenics USD 4.79M 1.15M 2025-12
Moderna USD 317M 50M 2025-12
Novartis USD 4.46B 99M 2025-12
Pfizer USD 5.02B 142M 2025-09
PTC Therapeutics USD 45.49M 8.87M 2025-12
Puma Biotechnology USD 6.39M 962K 2025-09
Regeneron Pharmaceuticals USD 5.83B 4.93B 2025-12
Roche Holding CHF 5.78B 1.27B 2025-12
Sangamo BioSciences USD 10.74M 7.46M 2025-06
Sarepta Therapeutics USD 280.84M 186.83M 2025-12
Takeda JPY 467.59B 28.61B 2025-12
TG Therapeutics USD 61.64M 72.38M 2025-09
Ultragenyx Pharmaceutical USD 40.57M 6.33M 2025-09
Vanda Pharmaceuticals USD 39.09M 33.28M 2024-12
Vertex Pharmaceuticals USD 3.43B 600.9M 2025-12